1-13 of 13
Authors: Andrew Scott
Journal Article
TMET-19. REWIRING OF CORTICAL GLUCOSE METABOLISM FUELS HUMAN BRAIN CANCER GROWTH Free
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Pages viii291–viii292, https://doi.org/10.1093/neuonc/noae165.1157
Published: 11 November 2024
Journal Article
TMIC-25. MICROGLIA IN THE GLIOBLASTOMA MICROENVIRONMENT SECRETE ACETYLATED AMINO ACIDS WHICH ASSIST IN THE REPAIR OF RADIATION INDUCED DNA DAMAGE Free
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii303, https://doi.org/10.1093/neuonc/noae165.1203
Published: 11 November 2024
Journal Article
CTNI-59. TUMOUR VOLUMES PREDICT PROGNOSIS AND RESPONSE TO TREATMENT WITH DEPATUXIZUMAB MAFADOTIN Free
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii110, https://doi.org/10.1093/neuonc/noae165.0426
Published: 11 November 2024
Journal Article
TMET-27. MACHINE LEARNING-BASED IDENTIFICATION OF METABOLIC FLUXES IN PATIENT BRAIN TUMORS Free
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii294, https://doi.org/10.1093/neuonc/noae165.1165
Published: 11 November 2024
Journal Article
CTNI-19. MYCOPHENOLATE MOFETIL TARGETS GLIOBLASTOMA DE-NOVO PURINE METABOLISM TO OVERCOME CHEMORADIATION RESISTANCE IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA Free
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Pages viii99–viii100, https://doi.org/10.1093/neuonc/noae165.0386
Published: 11 November 2024
Journal Article
DNAR-02. MICROGLIA IN THE GLIOBLASTOMA MICROENVIRONMENT ASSIST REPAIR OF RADIATION INDUCED DNA DAMAGE IN A CONTACT INDEPENDENT MANNER Free
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v98, https://doi.org/10.1093/neuonc/noad179.0368
Published: 10 November 2023
Journal Article
ATIM-23. PRELIMINARY FINDINGS OF A PHASE I SAFETY AND BIOIMAGING TRIAL OF KB004 (IFABOTUZUMAB) IN PATIENTS WITH GLIOBLASTOMA Free
Neuro-Oncology, Volume 21, Issue Supplement_6, November 2019, Page vi6, https://doi.org/10.1093/neuonc/noz175.022
Published: 11 November 2019
Journal Article
CSIG-25. EPIDERMAL GROWTH FACTOR RECEPTOR EXTRACELLULAR DOMAIN MISSENSE MUTATION A289V AS A DRIVER OF GLIOBLASTOMA INVASION AND PROLIFERATION Free
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi48, https://doi.org/10.1093/neuonc/noy148.191
Published: 05 November 2018
Journal Article
ACTR-55. TUMOR VOLUME AS A PREDICTOR OF RESPONSE TO ANTI-EGFR ADC ABT-414 Free
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi24, https://doi.org/10.1093/neuonc/noy148.087
Published: 05 November 2018
Journal Article
EXTH-56. EGFR EXTRACELLULAR DOMAIN POINT MUTANT A289V: A THERAPEUTICALLY TARGETABLE DRIVER OF GLIOBLASTOMA INVASION Free
Neuro-Oncology, Volume 19, Issue suppl_6, November 2017, Page vi85, https://doi.org/10.1093/neuonc/nox168.348
Published: 06 November 2017
Journal Article
PATH-29. MOLECULAR DETERMINANTS ASSOCIATED WITH RESPONSE AND RESISTANCE TO DEPATUXIZUMAB MAFODOTIN (ABT-414) IN PATIENTS WITH RECURRENT GLIOBLASTOMA Free
Neuro-Oncology, Volume 19, Issue suppl_6, November 2017, Pages vi176–vi177, https://doi.org/10.1093/neuonc/nox168.719
Published: 06 November 2017
Journal Article
ACTR-07. EFFICACY OF A NOVEL ANTIBODY-DRUG CONJUGATE (ADC), ABT-414, AS MONOTHERAPY IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (EGFRamp), RECURRENT GLIOBLASTOMA (rGBM) Free
Neuro-Oncology, Volume 18, Issue suppl_6, November 2016, Page vi2, https://doi.org/10.1093/neuonc/now212.006
Published: 07 November 2016
Journal Article
CSIG-06EGFRvIII REQUIRES OSMR AS A CO-RECEPTOR TO DRIVE GLIOBLASTOMA PATHOGENESIS Free
Neuro-Oncology, Volume 17, Issue suppl_5, November 2015, Page v67, https://doi.org/10.1093/neuonc/nov210.06
Published: 09 November 2015
